MIRA INFORM REPORT

 

 

Report Date :

18.08.2014

 

IDENTIFICATION DETAILS

 

Name :

ANGIOLAB, INC.

 

 

Registered Office :

1337, Gwanpyeong-dong, Yuseong-gu, Daejeon, Korea Rm. N514, Daedeok Industry-University Cooperation Bldg., Paichai Univ. 305-509

 

 

Country :

South Korea

 

 

Date of Incorporation :

03.06.1999

 

 

Com. Reg. No.:

314-81-26271

 

 

Legal Form :

Co., Ltd by Shares

 

 

Line of Business :

Manufacture of medicinal chemicals and antibiotics

 

 

No. of Employees

06

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

Payment Behaviour :

Unknown

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – June 1, 2014

 

Country Name

Previous Rating

(31.03.2014)

Current Rating

(01.06.2014)

South Korea

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

 

SOUTH KOREA ECONOMIC OVERVIEW

 

South Korea over the past four decades has demonstrated incredible growth and global integration to become a high-tech industrialized economy. In the 1960s, GDP per capita was comparable with levels in the poorer countries of Africa and Asia. In 2004, South Korea joined the trillion-dollar club of world economies, and is currently the world's 12th largest economy. Initially, a system of close government and business ties, including directed credit and import restrictions, made this success possible. The government promoted the import of raw materials and technology at the expense of consumer goods, and encouraged savings and investment over consumption. The Asian financial crisis of 1997-98 exposed longstanding weaknesses in South Korea's development model including high debt/equity ratios and massive short-term foreign borrowing. GDP plunged by 6.9% in 1998, and then recovered by 9% in 1999-2000. South Korea adopted numerous economic reforms following the crisis, including greater openness to foreign investment and imports. Growth moderated to about 4% annually between 2003 and 2007. South Korea's export focused economy was hit hard by the 2008 global economic downturn, but quickly rebounded in subsequent years, reaching 6.3% growth in 2010. The US-Korea Free Trade Agreement was ratified by both governments in 2011 and went into effect in March 2012. Throughout 2012 and 2013 the economy experienced sluggish growth because of market slowdowns in the United States, China, and the Eurozone. The administration in 2014 is likely to face the challenge of balancing heavy reliance on exports with developing domestic-oriented sectors, such as services. The South Korean economy's long term challenges include a rapidly aging population, inflexible labor market, dominance of large conglomerates (chaebols), and heavy reliance on exports, which comprise about half of GDP

 

Source : CIA

 

 

 

Basic Information

 

Basic

 

Company Name

ANGIOLAB, INC.

(Korean Company Name : “(주)안지오랩”)

Registered Address

1337, Gwanpyeong-dong, Yuseong-gu, Daejeon, Korea

Building

Rm. N514, Daedeok Industry-University Cooperation Bldg., Paichai Univ.

Zip Code

305-509

Tel

+82-42-867-5786

Fax

+82-42-867-5787

E-mail

angiolab@angiolab.co.kr

Website

www.angio-lab.co.kr

Trading Address

Rm. N514, Daedeok Industry-University Cooperation Bldg., Paichai Univ., 11-3, Techno 1-ro, Yuseong-gu, Daejeon, Korea

(Old Address System : Rm. N514, Daedeok Industry-University Cooperation Bldg., Paichai Univ., 1337, Gwanpyeong-dong, Yuseong-gu, Daejeon, Korea)

Tel

+82-42-867-5786

Fax

+82-42-867-5787

Other Address

 

Tel

 

Fax

 

Type

Export

Industry

Manufacture of Medicinal Chemicals and Antibiotics

  Main Business

Angiogenesis Inhibitor, Angiogenesis Assay Service

  Sub Business

 

Established (mm/dd/yyyy)

06/03/1999

 

Detailed Products

 

Activity

Detailed Products (UNSPSC)

Sell

Dietary supplements and nutritional therapy products(51191900)

Sell

Formulas and products for nutritional support(42231800)

 

CEO’s

 

Name

Kim Min-Young

Address

Suite 111-801, 71, Jeonmin-ro, Yuseong-gu, Daejeon, Korea

Date of Birth

03/17/1957

Title

President & CEO

Sex

Female

Nationality

Korean

 

 

 

 

Profiles

 

Capital (KRW)

986,291,000

Employees

6

Formation

Co., Ltd by Shares

Venture Business

Bank Details

Woori Bank

Kookmin Bank

Corporate Registered No.

160111-0082795

Business Registered No.

314-81-26271

Permit & Licenses

04/2007 ISO 9001

Shareholder Position

N/A

Company History

06/03/1999 Incorporated as the present name

12/22/1999 Designated as a Venture Business

02/03/2006 Increased the authorized shares to 2,000,000 Shares from 1,000,000 Shares

02/2007 Designated as an INNO-BIZ Company

08/23/2011 Moved to the present HQ address from 3-1, Doryong-dong, Yuseong-gu, Daejeon, Korea

06/04/2013 Increased capital to 986,291,000 KRW from 875,180,000 KRW

01/20/2014 Designated as a Venture Business again

 

 

Detailed Information

 

Management

 

Job Description

Title

Name

Sex

Nationality

Inauguration Date

President & CEO

M/S.

Kim Min-Young

Female

Korean

03/26/2014

Director

Mr.

Kim Joon-Han

Male

Korean

02/03/2003

Director

Mr.

Lee Sang-Min

Male

Korean

02/03/2006

Director

M/S.

Kim Eun-Hee

Female

Korean

03/26/2014

Director

M/S.

Park Myung-Ok

Female

Korean

03/26/2014

Auditor

Mr.

Kim Yong-Han

Male

Korean

03/31/2002

 

 

Financials

 

Year / Unit : KRW

Sales

Assets

Net Income

2013

 

 

 

2012

 

 

 

2011

 

 

 

2010

 

 

 

2009

181,000,000

1,700,000,000

-72,000,000

2008

75,000,000

1,897,000,000

-85,000,000

The latest & full financials are not available, and the Subject Company does not have any obligations to release its financials to the public.

 

Financial Description

 

Authorized Capital(KRW)

2,000,000,000

Paid-Up Capital(KRW)

986,291,000

Total Issued Shares

111,111

 

 

Products, Technologies, Services Description

 

Main Products & Services

Angiogenesis Inhibitor, Angiogenesis Assay Service

Detailed Products Spec.

 

Technologies Acquired

 

 

Trade Partners & Competitors

 

Suppliers

 

Customers

 

Competitors

JEIL PHARMACEUTICAL CO., LTD.(110111-0026652)

745-5, BANPO 1-DONG, SEOCHO-GU, SEOUL, KOREA

TEL:+82-2-549-7451  FAX:+82-2-549-7478

 

BORYUNG PHARM CO., LTD.(110111-0012560)

15TH FL., BORYEONG BLDG., 66-21, WONNAM-DONG, JONGNO-GU, SEOUL, KOREA

TEL:+82-2-708-8000  FAX:+82-2-742-6362

 

KWANGDONG PHARMACEUTICAL CO., LTD(110111-0152134)

4TH FL., GASAN BLDG., 1577-4, SEOCHO 3-DONG, SEOCHO-GU, SEOUL, KOREA

TEL:+82-2-6006-7777  FAX:+82-2-6006-702

 

 

Sales by Region (Activity & Markets)

 

The Subject exports to USA.

 

Court Action

 

Not Available.

 

 

News Clipping

 

--

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.61.06

UK Pound

1

Rs.101.84

Euro

1

Rs.81.56

 

INFORMATION DETAILS

 

Analysis Done by :

KAR

 

 

Report Prepared by :

NIS

 

               

RATING EXPLANATIONS

 

RATING

STATUS

PROPOSED CREDIT LINE

 

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

 

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

 

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

 

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

 

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

 

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

 

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

Credit not recommended

 

--

NB

 

New Business

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.